Who Buys Griseofulvin from India — 323 Importers Behind a $36.1M Market

The importation of Griseofulvin from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like HEKO PHARMACY LTD (Tanzania) and M/S. GITTOES PHARMACEUTICALS LTD. (Uganda) function as intermediaries, procuring large quantities to supply regional pharmacies and healthcare providers. Their bulk purchasing often leads to economies of scale, enabling competitive pricing.

• Hospital Groups: Organizations such as STE PRINCE PHARMA SARL (Congo DR) and CAMEG (Burkina Faso) represent hospital networks that import Griseofulvin to meet inpatient and outpatient needs. Their procurement is typically characterized by consistent, large-volume orders aligned with patient demand and treatment protocols.

• Retail Chains: CEYOKA (PRIVATE) LIMITED (Sri Lanka) and its subsidiary CEYOKA PRIVATE LIMITED are examples of retail pharmacy chains importing Griseofulvin to stock their outlets. Their purchasing patterns are influenced by consumer demand, leading to regular, moderate-sized orders to maintain inventory levels.

• Government Procurement: Entities like CAMEG (Burkina Faso) engage in tender-based purchasing to supply public healthcare facilities. This segment's buying behavior is driven by national health policies and budget allocations, often resulting in large, periodic orders following competitive bidding processes.

• Contract Manufacturers: Companies such as CIPLA USA INC UPS SUPPLY CHAIN SOLU (United States) and SANDOZ INC. (United States) may import Griseofulvin as raw material for formulation and distribution under their branding. Their procurement is typically large-scale and aligned with production schedules and market demand forecasts.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

For the top five importing countries of Griseofulvin from India, the import regulations are as follows:

• Tanzania:
• Regulatory Authority: Tanzania Medicines and Medical Devices Authority (TMDA).
• Import Registration Process: Requires submission of a dossier including product details, manufacturing information, and evidence of Good Manufacturing Practice (GMP) compliance.
• Estimated Timeline: Approximately 6-12 months, depending on the completeness of the application and any required inspections.
• Import Tariff/Duty: Pharmaceuticals are generally exempt from import duties, but a Value Added Tax (VAT) of 18% may apply.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Requires an Abbreviated New Drug Application (ANDA) for generic drugs, including bioequivalence studies and compliance with FDA regulations.
• Estimated Timeline: Typically 10 months for standard review, but can extend based on application specifics.
• Import Tariff/Duty: Pharmaceutical products are generally duty-free under HS Code 3004.

• Sri Lanka:
• Regulatory Authority: National Medicines Regulatory Authority (NMRA).
• Import Registration Process: Submission of a registration dossier, including product specifications, manufacturing details, and GMP certification.
• Estimated Timeline: Approximately 6-9 months, subject to the review process and any additional information requests.
• Import Tariff/Duty: Pharmaceuticals are typically exempt from import duties, but a VAT of 15% may be applicable.

• Congo DR:
• Regulatory Authority: Direction de la Pharmacie et du Médicament (DPM).
• Import Registration Process: Requires submission of a comprehensive dossier, including product information, manufacturing practices, and quality control measures.
• Estimated Timeline: Approximately 12 months, depending on the evaluation process and any required inspections.
• Import Tariff/Duty: Pharmaceuticals may be subject to import duties ranging from 5-10%, along with a VAT of 16%.

• Uganda:
• Regulatory Authority: National Drug Authority (NDA).
• Import Registration Process: Submission of a registration dossier, including product details, manufacturing information, and evidence of GMP compliance.
• Estimated Timeline: Approximately 6-12 months, subject to the review process and any additional requirements.
• Import Tariff/Duty: Pharmaceuticals are generally exempt from import duties, but a VAT of 18% may apply.

Compliance with these regulations is essential for market entry and sustained operations within these countries.

The demand for Griseofulvin in importing countries is influenced by several factors:

• Disease Prevalence: Griseofulvin is primarily used to treat fungal infections such as dermatophytosis. High prevalence rates of these conditions in tropical and subtropical regions drive demand.

• Government Healthcare Programs: Many countries have initiatives aimed at improving access to essential medicines. For instance, the World Health Organization (WHO) includes Griseofulvin in its Model List of Essential Medicines, encouraging member states to ensure its availability. (who.int)

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage increase the accessibility of essential medicines, including antifungal treatments, thereby boosting demand.

• WHO Essential Medicines List Procurement: Inclusion in the WHO Essential Medicines List facilitates procurement through international funding mechanisms and national health budgets, ensuring a steady demand. (who.int)

• Tender-Based Purchasing: Many governments and international organizations utilize tender systems to procure medicines, leading to bulk purchasing agreements that stabilize demand.

With 323 buyers across 97 countries, the market for Griseofulvin is both diverse and expansive, presenting significant opportunities for suppliers to meet the ongoing global demand.

The importation of Griseofulvin from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like HEKO PHARMACY LTD (Tanzania) and M/S. GITTOES PHARMACEUTICALS LTD. (Uganda) function as intermediaries, procuring large quantities to supply regional pharmacies and healthcare providers. Their bulk purchasing often leads to economies of scale, enabling competitive pricing.

• Hospital Groups: Organizations such as STE PRINCE PHARMA SARL (Congo DR) and CAMEG (Burkina Faso) represent hospital networks that import Griseofulvin to meet inpatient and outpatient needs. Their procurement is typically characterized by consistent, large-volume orders aligned with patient demand and treatment protocols.

• Retail Chains: CEYOKA (PRIVATE) LIMITED (Sri Lanka) and its subsidiary CEYOKA PRIVATE LIMITED are examples of retail pharmacy chains importing Griseofulvin to stock their outlets. Their purchasing patterns are influenced by consumer demand, leading to regular, moderate-sized orders to maintain inventory levels.

• Government Procurement: Entities like CAMEG (Burkina Faso) engage in tender-based purchasing to supply public healthcare facilities. This segment's buying behavior is driven by national health policies and budget allocations, often resulting in large, periodic orders following competitive bidding processes.

• Contract Manufacturers: Companies such as CIPLA USA INC UPS SUPPLY CHAIN SOLU (United States) and SANDOZ INC. (United States) may import Griseofulvin as raw material for formulation and distribution under their branding. Their procurement is typically large-scale and aligned with production schedules and market demand forecasts.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

For the top five importing countries of Griseofulvin from India, the import regulations are as follows:

• Tanzania:
• Regulatory Authority: Tanzania Medicines and Medical Devices Authority (TMDA).
• Import Registration Process: Requires submission of a dossier including product details, manufacturing information, and evidence of Good Manufacturing Practice (GMP) compliance.
• Estimated Timeline: Approximately 6-12 months, depending on the completeness of the application and any required inspections.
• Import Tariff/Duty: Pharmaceuticals are generally exempt from import duties, but a Value Added Tax (VAT) of 18% may apply.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Requires an Abbreviated New Drug Application (ANDA) for generic drugs, including bioequivalence studies and compliance with FDA regulations.
• Estimated Timeline: Typically 10 months for standard review, but can extend based on application specifics.
• Import Tariff/Duty: Pharmaceutical products are generally duty-free under HS Code 3004.

• Sri Lanka:
• Regulatory Authority: National Medicines Regulatory Authority (NMRA).
• Import Registration Process: Submission of a registration dossier, including product specifications, manufacturing details, and GMP certification.
• Estimated Timeline: Approximately 6-9 months, subject to the review process and any additional information requests.
• Import Tariff/Duty: Pharmaceuticals are typically exempt from import duties, but a VAT of 15% may be applicable.

• Congo DR:
• Regulatory Authority: Direction de la Pharmacie et du Médicament (DPM).
• Import Registration Process: Requires submission of a comprehensive dossier, including product information, manufacturing practices, and quality control measures.
• Estimated Timeline: Approximately 12 months, depending on the evaluation process and any required inspections.
• Import Tariff/Duty: Pharmaceuticals may be subject to import duties ranging from 5-10%, along with a VAT of 16%.

• Uganda:
• Regulatory Authority: National Drug Authority (NDA).
• Import Registration Process: Submission of a registration dossier, including product details, manufacturing information, and evidence of GMP compliance.
• Estimated Timeline: Approximately 6-12 months, subject to the review process and any additional requirements.
• Import Tariff/Duty: Pharmaceuticals are generally exempt from import duties, but a VAT of 18% may apply.

Compliance with these regulations is essential for market entry and sustained operations within these countries.

The demand for Griseofulvin in importing countries is influenced by several factors:

• Disease Prevalence: Griseofulvin is primarily used to treat fungal infections such as dermatophytosis. High prevalence rates of these conditions in tropical and subtropical regions drive demand.

• Government Healthcare Programs: Many countries have initiatives aimed at improving access to essential medicines. For instance, the World Health Organization (WHO) includes Griseofulvin in its Model List of Essential Medicines, encouraging member states to ensure its availability. (who.int)

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage increase the accessibility of essential medicines, including antifungal treatments, thereby boosting demand.

• WHO Essential Medicines List Procurement: Inclusion in the WHO Essential Medicines List facilitates procurement through international funding mechanisms and national health budgets, ensuring a steady demand. (who.int)

• Tender-Based Purchasing: Many governments and international organizations utilize tender systems to procure medicines, leading to bulk purchasing agreements that stabilize demand.

With 323 buyers across 97 countries, the market for Griseofulvin is both diverse and expansive, presenting significant opportunities for suppliers to meet the ongoing global demand.